7th May 2014 14:15
LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results.
The company said that there was no cell-related or immunological adverse events reported in any of the eleven patients treated in the phase I clinical trial. It said adverse events were related only to the implantation procedure or underlying co-morbidities, and that sustained reductions in neurological impairment and spasticity were observed in most patients.
ReNeuron recently announced that it had received unconditional approval to conduct a UK multi-site Phase II clinical trial to examine the efficacy of ReN001 in patients disabled by an ischaemic stroke.
It said that the Phase II study is now open for patient enrolment at the Glasgow clinical site, with other UK centres expected to follow.
The study will involve the treatment of up to 41 patients between eight and 12 weeks after their stroke. Patients will then be monitored on a number of validated stroke efficacy measures, up to six months post-treatment.
ReNeuron shares were up 2.4% Wednesday afternoon, trading at 3.33 pence.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
RENE.L